Pharmacokinetics and Pharmacodynamics of a Novel Pegylated Recombinant Human Granulocyte-Colony Stimulating Factor
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study is a four arm, parallel study.
Ten were administered a single subcutaneous administration of 30, 100 and 300 μg/kg of GCPGC
or placebo for each group (active:placebo=8:2). Eight were administered a single subcutaneous
administration of 100 μg/kg of Neulasta (an active comparator).